Filing summary
Period and entity discrepancy: The request identifies Lisata Therapeutics, Inc. and 2010 Q3, but the supplied filing is NeoStem, Inc.’s Form 10-Q for the quarter ended September 30, 2011, filed November 10, 2011. The summary below reflects the filing provided.
Business context
NeoStem reported three segments: Cell Therapy—United States, Regenerative Medicine—China, and Pharmaceutical Manufacturing—China. Its strategy was shifting toward cell therapy, including manufacturing and development, while it considered strategic alternatives for its 51% interest in Chinese pharmaceutical business Erye.
Financial performance and position
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $17.76m | $16.48m | $55.86m | $51.72m |
| Gross profit | $3.92m | $5.24m | $14.22m | $16.70m |
| Gross margin | 22.0% | 31.8% | 25.5% | 32.3% |
| Operating loss | $7.38m | $5.74m | $25.37m | $11.86m |
| Net loss attributable to common shareholders | $7.50m | $7.14m | $28.80m | $17.28m |
| Basic and diluted loss per share | $0.08 | $0.13 | $0.35 | $0.36 |
Revenue increased 7.8% in Q3 and 8.0% for the nine-month period. Gross profit and margins declined in both comparisons. The reported loss per share narrowed, but weighted-average shares rose substantially, to 94.1m in Q3 2011 from 56.8m in Q3 2010.
- Cash flow: Nine-month operating cash outflow was $17.52m, versus $3.18m in 2010; investing outflow was $3.13m versus $11.02m; financing inflow was $16.52m versus $10.99m. Cash and cash equivalents fell $3.90m from year-end to $11.71m.
- Liquidity: September 30 cash was $11.71m, restricted cash $1.43m, and working capital approximately $13.58m. A further $2.50m was held in escrow for Series E preferred obligations and was not available for current cash needs.
- Debt and obligations: Balance-sheet amounts included $7.81m in bank loans, $3.77m in notes payable, $3.68m in mortgages (current and long-term), and $20.53m due to related parties. Series E preferred stock had a reported carrying amount of $5.48m and required monthly redemption and 7% dividends.
- Capital raised and dilution: Nine-month net proceeds from stock issuance were $21.17m, including a July offering with $14.67m net proceeds. Common shares outstanding were 100.36m at September 30 and 107.32m as of November 8, 2011. The Aspire Capital agreement provided for up to $20m of stock purchases over 24 months, subject to conditions.
Material changes and management commentary
- Q3 revenue growth included $2.15m from PCT, acquired in January 2011. PCT contributed $5.57m revenue and approximately $4.04m net loss from acquisition through September 30.
- Erye revenue fell 5% in Q3 and 3% for the nine-month period. Management cited a shift away from lower-margin intermediates, antibiotic volume restrictions, price pressure, and currency effects. Higher new-facility costs and acquired-intangible amortization weighed on costs.
- Nine-month operating expenses rose 39% to $39.60m, including higher selling, general and administrative costs, R&D, acquisition-related expenses, and share-based compensation.
- NeoStem acquired Amorcyte on October 17, 2011, after quarter-end. AMR-001 was expected to enter a Phase 2 trial for acute myocardial infarction, with enrollment anticipated by the end of Q1 2012. Management estimated trial costs of approximately $12m over the first two years and up to $17m over five years, including manufacturing.
- Management said it anticipated seeking further capital and might use equity, debt, asset sales, grants, or other sources. It cautioned that financing might not be available on acceptable terms and that failure to raise funds could delay or discontinue development and expansion. No specific revenue or earnings guidance was provided.
Risks, contingencies, and unusual items
- Erye faced Chinese drug-pricing and proposed antibiotic-use restrictions; more than 70% of its manufactured drugs were on China’s essential drug list. Management discussed potential price reductions of up to 50% for two products and 75% for another; reductions experienced by September 30 were approximately 20%.
- Chinese regulatory approvals and registrations relating to NeoStem’s legal title to its Erye interest remained to be remediated. Management noted potential tax liabilities and penalties, and dependence on Erye officers’ cooperation. A sale of Erye was uncertain and subject to, among other things, EET’s right of first refusal.
- Erye patent and copyright disputes remained pending. Approximately $2.14m of Erye cash was frozen in connection with a copyright case; the filing said additional exposure beyond amounts accrued could not be reasonably assessed.
- PCT’s mortgage lender had waived covenant noncompliance through June 30, 2011; the next covenant measurement was December 31, 2011.
- The company reported a $1.15m R&D charge for acquired T-cell regulatory technology and significant non-cash share-based compensation. It also disclosed related-party arrangements, including Erye’s $20.53m payable to its 49% shareholder and management-affiliated ties to a charitable foundation that received a $0.61m stock contribution.
- Disclosure controls were judged effective at the reasonable-assurance level. Management said a previously identified material weakness in accounting for share-based awards had been remediated by March 31, 2011.
Important facts for investors to verify
- Confirm the filing identity and period: the supplied document is NeoStem’s 2011 Q3 10-Q, not a Lisata 2010 Q3 filing.
- Assess cash use, financing availability, and the potential dilution from outstanding options, warrants, preferred stock payments, and the Aspire Capital facility.
- Track Erye’s operating margins, regulatory remediation, litigation and frozen cash, related-party loan terms, and whether a divestiture proceeds.
- Monitor the AMR-001 Phase 2 timetable, trial funding needs, and milestone-based acquisition consideration.
- Review acquisition accounting, including the still-preliminary PCT purchase-price allocation, and the effects of non-cash compensation and derivative revaluations on reported results.